Fibrinogen Aα312 and Bβ448 polymorphisms are not related to bleeding during oral vitamin K-antogonist treatment [3]

Thrombosis and Haemostasis

Volumn 97, Issue 4, 2007, Pages 676-678

  Garcia, Andrea A ^a   van der Hoeven, Niels V ^a   Boellaard, Thierry N ^a   van der Heijden, Jeroen F ^a   Groot, Angelique P A ^a   Reitsma, Pieter H ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ALANINE; ANTIBIOTIC AGENT; ANTITHROMBOCYTIC AGENT; ARGININE; FIBRINOPEPTIDE A; FIBRINOPEPTIDE B; LYSINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; THREONINE; ANTICOAGULANT AGENT; BBETA FIBRINOGEN; FIBRINOGEN; FIBRINOGEN AALPHA; UNCLASSIFIED DRUG; VITAMIN K GROUP;

AMINO ACID SUBSTITUTION; ANTICOAGULATION; BLEEDING; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG SAFETY; FIBRINOGEN BLOOD LEVEL; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC RISK; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; THROMBOSIS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ANTAGONISM; GENETICS; GENOTYPE; MULTICENTER STUDY; NETHERLANDS; ORAL DRUG ADMINISTRATION; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

ACENOCOUMAROL; ADMINISTRATION, ORAL; ANTICOAGULANTS; CASE-CONTROL STUDIES; FIBRINOGEN; GENOTYPE; HEMORRHAGE; HUMANS; NETHERLANDS; ODDS RATIO; PHENPROCOUMON; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; VITAMIN K;

EID: 34247139355     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-10-0594     Document Type: Letter

References (9)

1. Scott EM, Ariëns RAS, Grant PE. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vase Biol 2004; 24: 1558-1566.
2. Standeven KF, Ariëns RAS, Grant PE. The molecular physiology and pathology of fibrin structure/function. Blood Rev 2005; 19: 275-288.
3. Maghzal GJ, Brennan SO, George PM. Fibrinogen B beta polymorphisms do not directly contribute to an altered in vitro clot structure in humans. Thromb Haemost 2003; 90: 1021-1028.
4. Carter AM, Catto AJ, Grant PJ. Association of the alpha-fibrinogen Thr312Ala polymorphism with post-stroke mortality in subjects with atrial fibrillation. Circulation 1999; 99: 2423-2426.
5. Standeven KF, Grant PJ, Carter AM, et al. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 2003; 107: 2326-2330.
6. Lim BC, Ariens RA, Carter AM, et al. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-1431.
7. Reitsma PH, van der Heijden JF, Groot AP, et al. A C1173T Dimorphism in the VKORC1 Gene Determines Coumarin Sensitivity and Bleeding Risk. PLoS Med 2005; 2: e312.
8. van der Heijden JF, Rekke B, Hutten BA, et al. Nonfatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX. J Thromb Haemost 2004; 2: 1104-1109.
9. Schneider S, Roessli D, Excoffier L. Arlequin: a software for population genetics data analysis. User manual ver 2.000. Ver. 2.000. Geneva: Genetics and Biometry Lab, Dept. of Anthropology, University of Geneva.